LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - William Blair upped their Q2 2025 EPS estimates for LENZ Therapeutics in a research note issued on Thursday, May 8th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings per share of ($0.66) for the quarter, up from their previous estimate of ($0.69). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics' Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($2.80) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.67) EPS.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02.
Several other research analysts have also issued reports on the stock. TD Cowen initiated coverage on shares of LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price target for the company. Piper Sandler began coverage on shares of LENZ Therapeutics in a report on Monday, April 14th. They set an "overweight" rating and a $51.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, May 8th. Finally, Citigroup upped their target price on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $46.60.
View Our Latest Stock Report on LENZ
LENZ Therapeutics Stock Up 0.2%
LENZ Therapeutics stock traded up $0.04 on Monday, hitting $27.38. The company's stock had a trading volume of 33,050 shares, compared to its average volume of 186,143. The company has a fifty day moving average price of $24.99 and a 200-day moving average price of $27.33. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93. The firm has a market cap of $770.75 million, a P/E ratio of -15.42 and a beta of 0.41.
Institutional Investors Weigh In On LENZ Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in LENZ Therapeutics in the fourth quarter valued at approximately $29,000. SG Americas Securities LLC lifted its stake in shares of LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock valued at $158,000 after purchasing an additional 935 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of LENZ Therapeutics by 14.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company's stock worth $229,000 after purchasing an additional 1,005 shares during the last quarter. Rhumbline Advisers boosted its position in shares of LENZ Therapeutics by 6.2% in the 4th quarter. Rhumbline Advisers now owns 18,754 shares of the company's stock worth $541,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of LENZ Therapeutics by 162.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after purchasing an additional 1,151 shares during the period. 54.32% of the stock is owned by institutional investors.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Articles
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
